Overview
Survodutide (BI 456906) is a dual glucagon/GLP-1 receptor agonist being researched for obesity and metabolic conditions. Clinical trials employed “once-weekly subcutaneous injections with dose-dependent weight loss during a 20-week escalation.”
Quick Start
– Reconstitution: Add 2.0 mL bacteriostatic water to create approximately 5.00 mg/mL solution
– Typical dosing range: 600–4800 mcg administered once weekly
– Insulin syringe math: At 5.00 mg/mL concentration, 1 unit equals approximately 50 mcg on U-100 syringes
– Storage (lyophilized): −20 °C (−4 °F)
– Storage (reconstituted): 2–8 °C (35.6–46.4 °F); protect from light; avoid freeze-thaw cycles
Dosing Protocol – Standard Gradual Approach
| Week | Dose (mcg) | Insulin Units |
|---|---|---|
| 1–4 | 600 | 12 units (0.12 mL) |
| 5–8 | 1200 | 24 units (0.24 mL) |
| 9–12 | 1800 | 36 units (0.36 mL) |
| 13–16 | 2400 | 48 units (0.48 mL) |
| 17–20 | 3600 | 72 units (0.72 mL) |
| 21–24 | 4800 | 96 units (0.96 mL) |
Frequency: Once per week via subcutaneous injection. Slower escalation strategies may reduce gastrointestinal adverse effects.
Reconstitution Steps
1. Draw 2.0 mL bacteriostatic water with sterile syringe
2. Inject slowly down vial wall to prevent foaming
3. Gently swirl or roll until fully dissolved (avoid shaking)
4. Label and refrigerate at 2–8 °C, protected from light
Supplies Needed (Example 16-Week Protocol)
– Peptide vials: 3 × Survodutide 10 mg vials (≈24 mg total)
– Insulin syringes: 16 U-100 syringes (one per weekly injection)
– Bacteriostatic water: 6.0 mL total (recommend one 10 mL bottle)
– Alcohol swabs: 32 swabs (recommend 100-count box)
Mechanism of Action
Survodutide activates both GLP-1 and glucagon receptors, supporting appetite control and increased energy expenditure. The compound design enables once-weekly dosing with demonstrated weight-loss effects in phase 2 obesity trials.
Injection Technique
– Clean vial stopper and injection site with alcohol; allow drying
– Pinch a skinfold and insert needle at 45–90° angle into subcutaneous tissue
– Do not aspirate before injecting
– Inject slowly and steadily; wait several seconds before withdrawal
– Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent lipohypertrophy
Benefits & Side Effects
Benefits:
– Dose-dependent weight reduction in overweight/obese populations
– Glycemic improvements in type 2 diabetes cohorts
Common adverse effects:
– Gastrointestinal symptoms (nausea, diarrhea, vomiting)
– Effects typically mitigated through slower titration protocols
– Overall tolerability rated as acceptable in studied populations with proper monitoring
Lifestyle Considerations
– Adopt balanced, calorie-appropriate diet emphasizing protein
– Incorporate both resistance and aerobic training
– Prioritize adequate sleep and stress management
Important Notes
– Use new sterile U-100 insulin syringes; dispose in sharps container
– Document each injection (dose, date, site) for consistency
– Do not aspirate before injection
– Allow vials to reach room temperature before opening to minimize condensation
Storage Summary
| State | Temperature | Conditions |
|---|---|---|
| Lyophilized | −20 °C (−4 °F) | Dry, dark conditions |
| Reconstituted | 2–8 °C (35.6–46.4 °F) | Protected from light; no freeze-thaw cycles |
Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult qualified healthcare professionals before starting any research protocol.